908 DEVICES INC. DL-,001

908 Devices announces a strategic focus on handheld chemical detectors intended to drive faster growth, improved margins and reduced cash burn. Revenue rose 23% in Q2 2026 to $16.1m, adjusted EBITDA loss for the quarter fell to below $2m, and the company reports $101.5m in cash with no debt. The 2026 revenue guidance was raised to $68–70m; recurring revenue is around 30% and is expected to grow further through the acquisition of NIRLab. 908 Devices highlights large market opportunities (opioid crisis, defense, border security) and an installed base of more than 4,100 devices with 700 customers in over 70 countries. » Altro su de.investing.com

908 Devices posted Q2 2026 revenue of $16.1 million, up 23% year‑over‑year, driven by FTIR product shipments and U.S. state and local demand. Adjusted EBITDA loss narrowed to about $1.9 million, a roughly 50% improvement, while adjusted gross margin rose to ~57%. The company closed the NIRLAB acquisition, sold 35+ NIRLAB units with multiyear subscriptions, and secured a $6 million ProtectIR order for APAC. Cash and equivalents were $101.5 million with no debt, and full‑year revenue guidance was raised to $68–70 million, excluding potential AVCAD program upside. » Altro su finance.yahoo.com

At the Growth Conference, 908 Devices presented a strategic shift away from medical technology toward handheld mass spectrometers for defense, law enforcement and public safety. The company has more than USD 100 million in liquidity and an adjusted EBITDA in the mid-single-digit millions, providing several years of financial runway. The product range spans the low-cost NIRLab to the flagship MX908; a new, more compact MX908 generation is planned for late 2026. Government grant programs and military projects such as AVCAD, together with growing international demand, are cited as the main growth drivers. » Altro su de.investing.com